Adial Pharmaceuticals, Inc. (ADIL)

NasdaqCM: ADIL · 即時價格 · USD

6.66

+0.34 (5.38%)

收盤價： Sep 03, 2026, 3:55 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

5.38% (1D)

買價	4.57
市值	19.5M
營收 (ttm)	n/a
淨利（ttm）	-57.8M
	1.29
	-17.71
	n/a
	-0.89
P/B (ttm)	-0.46
P/S (ttm)	0.00
財報日期	n/a

賣價	3.08
成交量	52,770
20 日平均成交量	420,508
開盤價	6.32
前收盤價	6.32
當日區間	6.25 - 6.80
52 週範圍	1.31 - 10.75
分析師	購買
目標價	8 (20.12%)
股利	n/a
除息日	n/a

關於 ADIL

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Jul 27, 2018

員工 5

證券交易所 NasdaqCM

股票代號 ADIL

網站 https://www.adial.com

完整的公司簡介

財務表現

Adial Pharmaceuticals 在 2025 年的營收為 0，較前一年的 0 增加 undefined%。淨利為 -7.98M，較前期減少 -39.56%。

財務報表

分析師預測

根據 3 位分析師的評等，ADIL 的平均評等為「Buy」。12 個月目標價為 8，較最新價格有 20.12% 的上漲空間。

股票預測

財報驚奇

Adial Pharmaceuticals 已於 Aug 14, 2026 公布季度財報：

營收為 $0 低於預期 $0, 年增 NaN% 成長.
每股盈餘為 -1.29 低於預期 -0.38, 年增 71.33% 成長.

價格為何變動

新聞動態

2 月前 · MT Newswires

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index and the State Street

2 月前 · Stocktwits

ADIL Stock Eyes Best Day In Over 5 Years — Major Pipeline Overhaul And $64M Raise Fuel Rally

Adial on Thursday announced that it has bought privately held Azora Therapeutics.

8 月前 · Zacks

Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?

Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.

11 月前 · The Fly

CoreWeave initiated, Instacart downgraded: Wall Street's top analyst calls

11 月前 · Benzinga

Adial Pharmaceuticals Highlights Favorable Comments From FDA Meeting For Lead Program In Alcohol Use Disorder

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) on Tuesday received the final meeting minutes from its End of Phase 2 (EOP2) Meeting with the U.S. Food and Drug Administration (FDA) held in July. The minute...

Adial Pharmaceuticals, Inc. (ADIL)